Key result
Heart failure patients average ~6 potential drug-drug interactions at hospital discharge.
Why the study?
Heart failure patients are at risk of hazardous potential drug-drug interactions, especially with co-administered drugs with narrow therapeutic index, but the prevalence and severity were not well characterized.
What is the prevalence and severity of potential drug-drug interactions in hospital discharged heart failure patients?
Observational (n=239)
No
What is the prevalence and severity of potential drug-drug interactions in hospital discharged heart failure patients?
Answers are grounded in this paper and cite their sources.
Heart failure patients are at high risk for potential drug-drug interactions at hospital discharge, highlighting the need for careful prescription screening.
Objective: The aim of the present study was to assess the prevalence, risk rating and the severity of hazardous pDDIs (potential drug-drug interactions) in the prescribed pharmacotherapy in the hospital discharged heart failure (HF) patients, primarily with co-administered drugs with narrow therapeutic index (statins, anticoagulants, antithrombotic drugs). Methods: The prescriptions of chronic heart failure patients for one year (January-December 2014) were analyzed for pDDIs through Lexi-interact® software. DDIs belonging to the categories D (Consider therapy modification) and X (Avoid combination) and/or severity of drug interaction-major, were selected for the study. Results: After reviewing the medical records of 985 patients, 239 patients were selected based on the criteria mentioned above. The average number of prescription drugs at hospital discharge was 7.27 medications (±1.84 SD) per patient. The total number of pDDIs was 1483 or approximately 6.2 (±3.89 SD) pDDIs per patient. With respect to the risk rating, in categories D and X were detected 76 (5.12 %) and 2 (0.13 %) pDDI, respectively. The major pDDIs were 108 (7.28 %). Conclusion: HF patients are at high risk of pDDIs. Screening of prescriptions for pDDIs and monitoring of pharmacotherapy in terms of response and associated adverse drug events will contribute to patient safety.
No takes yet. Share an insight, caveat, or question.
Georgiev et al. (2019) conducted an observational in Heart failure (n=239). Prescribed pharmacotherapy (polypharmacy) was evaluated on Prevalence, risk rating, and severity of hazardous potential drug-drug interactions (pDDIs). Among 239 heart failure patients, there was an average of 6.2 potential drug-drug interactions per patient, with 5.12% classified as requiring therapy modification and 7.28% as major severity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: